Medical Bulletin 03/June/2026 - Video

Here are the top medical news for today:

Experimental Pancreatic Cancer Drug Shows Survival Benefit in Major Trial

A long-awaited breakthrough may finally be emerging against one of the deadliest cancers.

Researchers have reported that an experimental drug called daraxonrasib nearly doubled survival in patients with metastatic pancreatic cancer, offering fresh hope for a disease that has long had limited treatment options. The findings were presented at the American Society of Clinical Oncology (ASCO) annual meeting and simultaneously published in the New England Journal of Medicine.

Pancreatic cancer remains one of the most lethal cancers because it is often diagnosed only after it has spread beyond the pancreas. Survival rates for advanced disease remain poor, and treatment options after first-line chemotherapy are limited.

The global Phase 3 clinical trial enrolled 500 patients with metastatic pancreatic cancer whose disease had progressed after an initial round of chemotherapy. Participants who received daraxonrasib achieved a median overall survival of 13.2 months, compared with 6.7 months among those treated with standard chemotherapy. The drug also reduced the risk of death by 60%.

Daraxonrasib is an oral targeted therapy designed to block RAS proteins, a family of cancer-driving molecules involved in the growth and spread of most pancreatic tumors

Experts say the results represent one of the most significant advances seen in metastatic pancreatic cancer in years. Beyond extending survival, the treatment appeared to help patients maintain a better quality of life with fewer symptoms and side effects than conventional chemotherapy.

For some participants, the benefits were dramatic. One patient reported that a tumor that had spread from the pancreas to the liver shrank by 50% after starting treatment. Another patient experienced a 40% reduction in tumor size while keeping the primary pancreatic tumor stable, allowing her to focus on spending time with family and planning for the future.

Although daraxonrasib has not yet received U.S. Food and Drug Administration approval, regulators have already authorized an expanded access program for eligible patients. If approved, researchers believe the drug could mark a major shift in the treatment of metastatic pancreatic cancer, offering patients longer survival and improved quality of life.

REFERENCE: ileen M. O’Reilly, M.D., Zev A. Wainberg, M.D., Andrew E. Hendifar, M.D., Mitesh J. Borad, M.D., Filippo Pietrantonio, M.D., Shubham Pant, M.D., Pascal Hammel, M.D; Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer; New England Journal of Medicine; DOI: 10.1056/NEJMoa2605555

Scientists Identify Overlooked Organ That May Predict Lifespan and Health

A tiny organ hidden behind the breastbone may hold one of the biggest secrets to healthy aging.

Scientists at Mass General Brigham have discovered that the thymus—an immune system organ long believed to become largely irrelevant after childhood—may play a crucial role in determining how long people live, their risk of major diseases, and even how well they respond to cancer treatment.

Published in Nature, two large studies challenge decades of scientific assumptions about the thymus. Researchers used artificial intelligence to analyze CT scans from more than 25,000 adults and found that people with healthier thymuses had significantly better health outcomes than those with poorer thymic function.

The thymus is responsible for training T cells, the immune system's frontline defenders against infections, cancer, and other threats. Although the organ naturally shrinks after puberty, the new findings suggest it continues to influence immune health throughout adulthood.

Researchers developed an AI-based "thymic health" score by measuring the organ's size, structure, and composition. The results were striking. Individuals with healthier thymuses had nearly a 50% lower risk of death from any cause, a 63% lower risk of dying from cardiovascular disease, and a 36% lower risk of developing lung cancer compared with those with poorer thymic health.

In a second study involving more than 1,200 cancer patients receiving immunotherapy, researchers found that thymic health also influenced treatment success. Patients with healthier thymuses had a 37% lower risk of cancer progression and a 44% lower risk of death during treatment.

Scientists believe the thymus helps maintain a diverse pool of T cells, allowing the immune system to better recognize and attack cancer cells. A decline in thymic function may reduce that ability, limiting the effectiveness of modern immunotherapies.

While more research is needed, the findings suggest the thymus is far more than a childhood organ. It may be a key factor in longevity, disease resistance, and the body's ability to fight cancer throughout life.

REFERENCE: Simon Bernatz, Vasco Prudente, Suraj Pai, Asbjørn K. Attermann, Yumeng Cao, Jiachen Chen, Asya Lyass, Borek Foldyna, Leonard Nürnberg, Keno Bressem, Christopher Abbosh, Charles Swanton, Mariam Jamal-Hanjani, Michael T. Lu, Joanne M. Murabito, Kathryn L. Lunetta, Nicolai J. Birkbak, Hugo J. W. L. Aerts. Thymic health consequences in adults. Nature, 2026; 652 (8111): 986 DOI: 10.1038/s41586-026-10242-y

Researchers Question BMI’s Accuracy in Detecting Obesity-Related Diseases

A healthy BMI may not tell the whole story when it comes to obesity.

A new study from Keck Medicine of USC, published in the Annals of Internal Medicine, suggests that millions of people who are considered a healthy weight by traditional standards may actually have obesity-related health risks that go undetected. The findings challenge the long-standing reliance on Body Mass Index (BMI), a measure based only on height and weight.

Researchers found that about one in four adults with a normal BMI met the criteria for what experts now call clinical obesity. Even more striking, half of those classified as overweight by BMI would be considered obese under the newer definition.

Unlike BMI, clinical obesity focuses on excess fat around the abdomen, known as adipose fat, which is strongly linked to inflammation and chronic disease. This deeper abdominal fat can damage organs and increase the risk of conditions such as heart disease, diabetes, high blood pressure, liver disease, and certain cancers.

The study analyzed data from nearly 5,600 adults who participated in the National Health and Nutrition Examination Survey. Researchers compared BMI classifications with a newer assessment method that uses waist circumference, waist-to-hip ratio, and waist-to-height ratio. Individuals who showed excess abdominal fat and obesity-related health problems were classified as clinically obese, regardless of their BMI.

BMI has important limitations because it cannot distinguish between fat, muscle, and bone. A muscular person may have a high BMI without excess fat, while someone with little muscle mass can have a normal BMI but still carry harmful levels of abdominal fat.

The findings suggest that relying solely on BMI could cause many at-risk individuals to miss out on early interventions, including lifestyle counseling, weight-management programs, medications, or other treatments that could improve long-term health outcomes.

The message is clear: a "normal" BMI does not always guarantee metabolic health, and obesity may be more common than previously recognized.

REFERENCE: Elhence, H., et al. (2026). National Prevalence of Clinical Obesity by BMI Class: A National Cross-Sectional Study. Annals of Internal Medicine. DOI: 10.7326/annals-25-05287. https://www.acpjournals.org/doi/10.7326/ANNALS-25-05287